Stage IV Non-Small Cell Lung Cancer (NSCLC) research hub

A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.